Genetic carrier screening
QHerit®, our innovative genetic carrier screening portfolio provides clinically relevant, right-sized panels that deliver information that you and your patients need to help plan their futures.
Breast cancer is the second most common cancer in women in the United States.1 While all women are at risk for getting breast cancer,2 breast cancer in young women is more likely to be hereditary than breast cancer in older women.3
Hereditary cancer comprises about 5%-10% of all cancers4
A complete portfolio of hereditary cancer tests, services, and expert analysis from Quest Advanced Oncology helps you understand patient risk and is the first step in our approach to patient care.
Women and men who carry variants in the BRCA1 and BRCA2 genes are at a higher risk for developing certain types of cancer. These include cancers of the breast, ovary, prostate, and pancreas. There may also be an increased risk for melanoma. Having a variant does not mean your patient has cancer, only that they are at a higher risk for developing cancer.
A variant in any of several genes can cause Lynch syndrome. People with a variant in 1 of these genes have a higher risk for some types of cancer, including cancers of the colon, uterus, ovary, and stomach. Although the risk for cancer is increased, not everyone with Lynch syndrome will develop cancer. Knowing if your patients have a variant allows you to take steps to help them reduce the risk of developing cancer.
Quest Advanced Oncology’s hereditary cancer solutions website includes our complete portfolio of tests and panels, as well as additional professional resources to help address a variety of patient questions and concerns:
Our guideline-based quiz can help your patients identify whether they have personal or family history that indicates a risk of hereditary cancer.
Our team of genetic counselors is available to help with test selection and result interpretation to provide clinical insights that can help you and your patients make more informed decisions about their care pathway.
References:
Image content features models and is intended for illustrative purposes only.
QHerit®, our innovative genetic carrier screening portfolio provides clinically relevant, right-sized panels that deliver information that you and your patients need to help plan their futures.
Learn about our spinal muscular atrophy screening that can help provide greater insights and minimize uncertainty.
Certified Genomic Science Specialists are available to help with test selection and results interpretation 1.866.GENE.INFO (1.866.436.3463)
Review the latest data from our new 2020 Health Trends™ study.
Contact us to receive additional information on our lab tests, services, and coverage